Goldman Sachs analyst Asad Haider raised the firm’s price target on Johnson & Johnson to $240 from $213 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson and Johnson’s Rybrevant Faspro combination in NSCLC approved by FDA
- Johnson & Johnson announces FDA approved Rybrevant in NSCLC patients
- 3 Best ETFs to Invest In, According to AI Analyst, 12/17/2025
- Johnson & Johnson price target raised to $240 from $230 at RBC Capital
- Johnson & Johnson Rival Medline Pulls Off $6B IPO, Topping 2025 Deal Table